Results 141 to 150 of about 801,972 (259)
Social prescribing as a tool for integrated care-insights from a cross-sectional study with German general practitioners. [PDF]
Haxhija DE +4 more
europepmc +1 more source
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Evaluating the structure and process of effective integrated care for people with multiple long-term conditions: systematic review protocol. [PDF]
Todowede O +6 more
europepmc +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Care without walls: Generalist-led integrated home health for life’s final chapter
Wei Chyi Rae-Ann Tan +5 more
doaj +1 more source
Effects of integrated care on patients with COPD and comorbidities: a systematic review. [PDF]
Guan X, Xia Y, Ai J, Shi Z, Wei X, He P.
europepmc +1 more source
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Application of Decision-Analytic Models to Evaluate Integrated Care Interventions for Cardiometabolic Multimorbidity: A Systematic Review. [PDF]
Wambiya EOA +6 more
europepmc +1 more source
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source
Improving management of acute asthma in children through an integrated care pathway. [PDF]
Montejo M +8 more
europepmc +1 more source

